Clinical trial • Phase II • Oncology

RINATABART SESUTECAN for Non-small cell lung cancer | Locally advanced or metastatic non-small cell lung cancer

Phase II trial of RINATABART SESUTECAN for Non-small cell lung cancer | Locally advanced or metastatic non-small cell lung cancer.

Overview

Trial Therapeutic Area
Oncology
Trial Disease
Non-small cell lung cancer | Locally advanced or metastatic non-small cell lung cancer
Trial Stage
Phase II
Drug Modality
ADC | Peptide/protein/enzyme
Paediatric Trial
Yes

Key dates

Initial CTIS Submission Date
01-12-2025
First CTIS Authorization Date
14-04-2026

Trial design

open-label, none/not specified-controlled Phase II trial in Belgium, France, Germany and others.

Open Label
Yes
Comparator
None/Not specified
Biomarker Stratified
True, actionable genetic alterations (AGAs): strata = AGA vs no AGA
Target Sample Size
93
Trial Duration For Participant
1095

Eligibility

Recruits 93 paediatric patients.

Vulnerable Population
Vulnerable populations selected. Subject information and informed consent form (SIS-ICF) documents are provided for pregnant participants and pregnant partners and there is a specific 'Child data collection' SIS-ICF document (French). Multiple country-specific SIS-ICF and consent documents are included (e.g., Dutch, French, German, Hungarian, Italian, Spanish, Polish). The presence of child data collection and pregnancy-specific ICFs indicates inclusion of children and pregnant participants as vulnerable populations; specific parental consent/assent procedures are referenced by the presence of child data collection and SIS-ICF documents but detailed assent/consent process text is not provided in the extracted content.

Inclusion criteria

  • {"criterion_text":"- Participant has histologically or cytologically confirmed metastatic or locally advanced NSCLC of adenocarcinoma histology, not amenable to curative surgery or radiotherapy.\n- Participant must have radiological disease progression while on or after receiving the most recent regimen.\n- Participants either may have actionable genetic alterations (AGAs) or no AGAs.\n- Participant has measurable disease according to RECIST v1.1.\n- Participant has an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1 within 7 days of Cycle 1 Day 1."}

Exclusion criteria

  • {"criterion_text":"- Participant has NSCLC with histology other than adenocarcinoma\n- Participant has a past or current malignancy other than the inclusion diagnosis before the planned first dose of trial treatment, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death (eg, 5- year OS ≥ 90%), including, but not limited to, adequately treated cervical carcinoma of stage 1B or less, in situ basal cell or squamous cell skin carcinoma, in situ bladder cancer, ductal carcinoma in situ, or any past malignancy considered cured for ≥ 3 years.\n- Participants with newly identified or known unstable (eg, progressing brain metastases) or symptomatic central nervous system (CNS) metastases or history of carcinomatous meningitis (also known as leptomeningeal disease). Participants with history of spinal cord compression (from disease). Participants with previous CNS-directed therapy (eg, radiotherapy and/or surgery) for brain metastases may participate provided lesion(s) are radiologically stable (ie, without evidence of progression) for at least 28 days by repeat imaging."}

Endpoints

Primary endpoints

  • {"endpoint_text":"- Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as Assessed by Investigator [Time Frame: Approximately 3 years]","definition_or_measurement_approach":"ORR measured per RECIST v1.1 assessed by investigator; time frame approximately 3 years."}

Secondary endpoints

  • {"endpoint_text":"- 1.Duration of Response (DOR) per RECIST v1.1 as Assessed by Investigator [Time Frame: Approximately 4 years]\n- 2.Disease Control Rate (DCR) per RECIST v1.1 as Assessed by Investigator [Time Frame: Approximately 4 years]\n- 3.Progression-free Survival (PFS) [Time Frame: Approximately 4 years]\n- 4.Overall Survival (OS) [Time Frame: Approximately 4 years]\n- 5.Maximum (Peak) Observed Serum Drug Concentration (Cmax) of Rina-S Related Analytes [Time Frame: Approximately 12 months]\n- 6.Time to Reach Maximum (Peak) Serum Drug Concentration (Tmax) of Rina-S Related Analytes[Time Frame: Approximately 12 months]\n- 7.Number of Participants with Antidrug Antibodies (ADAs) [Time Frame: Approximately 12 months]\n- 8.Number of Participants with Treatment-emergent Adverse Events (TEAEs) [Time Frame: Approximately 4 years]","definition_or_measurement_approach":"DOR, DCR measured per RECIST v1.1 as assessed by investigator (time frame ~4 years). PFS and OS measured as standard survival endpoints (time frame ~4 years). PK endpoints (Cmax, Tmax) measured for Rina-S related analytes (time frame ~12 months). Immunogenicity endpoint: number with ADAs (time frame ~12 months). Safety: number with TEAEs (time frame ~4 years)."}

Recruitment

Digital Remote Recruitment
True, Mural Health digital recruitment materials (Mural participant form, link verbiage, mobile web and app screenshots, privacy policy, terms & conditions, notifications, travel/reference guides) are included; these indicate use of an app/web platform for participant engagement and remote data collection.
Planned Sample Size
93
Recruitment Window Months
9
Consent Approach
Informed consent is handled via country-specific SIS-ICF (subject information and informed consent form) documents. Main SIS-ICF forms and specific SIS-ICF documents for pregnant participants, pregnant partners, and child data collection are provided. Multiple language versions are present across countries (documents listed in Dutch, French, German, Hungarian, Italian, Spanish, Polish, and English). Consent is obtained using these SIS-ICF documents; child-specific data collection forms and pregnancy-specific ICFs indicate tailored consent materials for vulnerable subgroups (parental consent/child data collection forms are included though detailed assent procedures are not explicit in the extracted content).

Methods

  • Physician-to-Physician letters (K2 documents listed for multiple countries) — channel: direct communication between treating physicians to notify potential referring physicians about the trial.
  • General Practitioner letters (K2 documents present e.g., France) — channel: letters to GPs to assist identification/referral of potential participants.
  • Country-specific recruitment procedures (K1 Recruitment Procedure documents listed for Belgium, France, Germany, Italy, Spain, Netherlands, Poland, Hungary) — outlines local recruitment workflows per country (documented as K1 for each country).
  • Digital/remote recruitment via Mural Health platform (Hungary-specific materials listed: Mural Health Participant Form, Mural Link Verbiage, Mural mobile web and app screenshots, Mural privacy/terms, patient app reference guides) — channel: digital app/web targeted to participants to support remote engagement and study procedures.

Geography

Total Number Of Sites
49
Total Number Of Participants
107

Belgium

Earliest CTIS Part Ii Submission Date
09-01-2026
Latest Decision Or Authorization Date
16-04-2026
Processing Time Days
97
Number Of Sites
6
Number Of Participants
12

Sites

Site Name
Institut Jules Bordet
Department Name
Lung Oncology
Principal Investigator Name
Mariana Da Rocha Almeida Brandao
Principal Investigator Email
mariana.brandao@hubruxelles.be
Contact Person Name
Mariana Da Rocha Almeida Brandao
Contact Person Email
mariana.brandao@hubruxelles.be
Site Name
UZ Leuven
Department Name
Respiratory Oncology
Principal Investigator Name
Christophe Dooms
Principal Investigator Email
christophe.dooms@uzleuven.be
Contact Person Name
Christophe Dooms
Contact Person Email
christophe.dooms@uzleuven.be
Site Name
Universitair Ziekenhuis Antwerpen
Department Name
Thoracic Oncology
Principal Investigator Name
Reinier Wener
Principal Investigator Email
reinier.wener@uza.be
Contact Person Name
Reinier Wener
Contact Person Email
reinier.wener@uza.be
Site Name
CHU Helora
Department Name
Medical Oncology
Principal Investigator Name
Gaetan Catala
Principal Investigator Email
gaetan.catala@helora.be
Contact Person Name
Gaetan Catala
Contact Person Email
gaetan.catala@helora.be
Site Name
Algemeen Ziekenhuis Delta
Department Name
Pneumology
Principal Investigator Name
Ingel Demedts
Principal Investigator Email
ingel.demedts@azdelta.be
Contact Person Name
Ingel Demedts
Contact Person Email
ingel.demedts@azdelta.be
Site Name
Jessa Ziekenhuis
Department Name
Pneumology
Principal Investigator Name
Kristof Cuppens
Principal Investigator Email
kristof.cuppens@jessazh.be
Contact Person Name
Kristof Cuppens
Contact Person Email
kristof.cuppens@jessazh.be

France

Earliest CTIS Part Ii Submission Date
01-04-2026
Latest Decision Or Authorization Date
16-04-2026
Processing Time Days
15
Number Of Sites
7
Number Of Participants
16

Sites

Site Name
Hospices Civils De Lyon
Department Name
Pneumology
Principal Investigator Name
Sébastien COURAUD
Principal Investigator Email
sebastien.couraud@chu-lyon.fr
Contact Person Name
Sébastien COURAUD
Contact Person Email
sebastien.couraud@chu-lyon.fr
Site Name
Centre Hospitalier Regional De Marseille
Department Name
Multidisciplinary Oncology and Therapeutic Innovation
Principal Investigator Name
Pascale TOMASINI
Principal Investigator Email
Pascale.tomasini@ap-hm.fr
Contact Person Name
Pascale TOMASINI
Contact Person Email
Pascale.tomasini@ap-hm.fr
Site Name
Institut Curie
Department Name
Pneumology
Principal Investigator Name
Nicolas GIRARD
Principal Investigator Email
Nicolas.girard2@curie.fr
Contact Person Name
Nicolas GIRARD
Contact Person Email
Nicolas.girard2@curie.fr
Site Name
Fondation Hopital Saint Joseph
Department Name
Oncology
Principal Investigator Name
Carole HELISSEY
Principal Investigator Email
chelissey@ghpsj.fr
Contact Person Name
Carole HELISSEY
Contact Person Email
chelissey@ghpsj.fr
Site Name
Hospices Civils De Lyon (Pierre Benite site)
Department Name
Pneumology
Principal Investigator Name
Sébastien COURAUD
Principal Investigator Email
sebastien.couraud@chu-lyon.fr
Contact Person Name
Sébastien COURAUD
Contact Person Email
sebastien.couraud@chu-lyon.fr
Site Name
Hospices Civils De Lyon (Bron site)
Department Name
Pneumology
Principal Investigator Name
Sébastien COURAUD
Principal Investigator Email
sebastien.couraud@chu-lyon.fr
Contact Person Name
Sébastien COURAUD
Contact Person Email
sebastien.couraud@chu-lyon.fr
Site Name
Assistance Publique Hopitaux De Paris
Department Name
Pneumology
Principal Investigator Name
Marie WISLEZ
Principal Investigator Email
marie.wislez@aphp.fr
Contact Person Name
Marie WISLEZ
Contact Person Email
marie.wislez@aphp.fr

Germany

Earliest CTIS Part Ii Submission Date
25-03-2026
Latest Decision Or Authorization Date
15-04-2026
Processing Time Days
21
Number Of Sites
3
Number Of Participants
12

Sites

Site Name
Thoraxklinik Heidelberg gGmbH
Department Name
Department of Thoracic Oncology
Principal Investigator Name
Farastuk Bozorgmehr
Principal Investigator Email
farastuk.bozorgmehr@med.uni-heidelberg.de
Contact Person Name
Farastuk Bozorgmehr
Site Name
Evangelische Lungenklinik Berlin Krankenhausbetriebs gGmbH
Department Name
Clinic for Pneumology
Principal Investigator Name
Christian Grohe
Principal Investigator Email
christian.grohe@pgdiakonie.de
Contact Person Name
Christian Grohe
Contact Person Email
christian.grohe@pgdiakonie.de
Site Name
Universitaetsklinikum Essen AöR
Department Name
Department of medical oncology
Principal Investigator Name
Halime Kalkavan
Principal Investigator Email
Halime.kalkavan@kuk-essen.de
Contact Person Name
Halime Kalkavan
Contact Person Email
Halime.kalkavan@kuk-essen.de

Hungary

Earliest CTIS Part Ii Submission Date
23-02-2026
Latest Decision Or Authorization Date
20-04-2026
Processing Time Days
56
Number Of Sites
3
Number Of Participants
5

Sites

Site Name
Bacs-Kiskun Varmegyei Oktatokorhaz
Department Name
Onkoradiológiai Központ
Principal Investigator Name
Judit KOCSIS
Principal Investigator Email
kocsisjucidr@gmail.com
Contact Person Name
Judit KOCSIS
Contact Person Email
kocsisjucidr@gmail.com
Site Name
Komarom-Esztergom Varmegyei Szent Borbala Korhaz
Department Name
Tüdőgyógyászati Onkológiai Gondozó
Principal Investigator Name
Nóra BITTNER
Principal Investigator Email
nora_bittner@yahoo.ca
Contact Person Name
Nóra BITTNER
Contact Person Email
nora_bittner@yahoo.ca
Site Name
Clinic Of Pulmonology Semmelweis University
Department Name
-
Principal Investigator Name
Veronika MÜLLER
Principal Investigator Email
muller.veronika@med.semmelweis-univ.hu
Contact Person Name
Veronika MÜLLER

Italy

Earliest CTIS Part Ii Submission Date
30-03-2026
Latest Decision Or Authorization Date
15-04-2026
Processing Time Days
16
Number Of Sites
7
Number Of Participants
12

Sites

Site Name
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Department Name
UOC Oncologia Medica
Principal Investigator Name
Emilio Bria
Principal Investigator Email
Emilio.bria@policlinicogemelli.it
Contact Person Name
Emilio Bria
Site Name
Azienda Unita Sanitaria Locale Della Romagna
Department Name
U.O. Oncologia, Dipartimento OncoEmatologico
Principal Investigator Name
Manolo D’Arcangelo
Principal Investigator Email
manolo.darcangelo@auslromagna.it
Contact Person Name
Manolo D’Arcangelo
Site Name
Istituto Di Candiolo Fondazione Del Piemonte Per L'Oncologia IRCCS
Department Name
Medical Oncology Department
Principal Investigator Name
Vanesa Gregorc
Principal Investigator Email
vanesa.gregorc@ircc.it
Contact Person Name
Vanesa Gregorc
Contact Person Email
vanesa.gregorc@ircc.it
Site Name
Azienda Ospedaliera Universitaria Universita' Degli Studi Della Campania Luigi Vanvitelli
Department Name
Department of PrecisionMedicine
Principal Investigator Name
Floriana Morgillo
Principal Investigator Email
Floriana.morgillo@unicampania.it
Contact Person Name
Floriana Morgillo
Site Name
Azienda Ospedaliero-Universitaria San Luigi Gonzaga
Department Name
SCSU Medical Oncology
Principal Investigator Name
Silvia Novello
Principal Investigator Email
Silvia.novello@unito.it
Contact Person Name
Silvia Novello
Contact Person Email
Silvia.novello@unito.it
Site Name
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
Department Name
S.S.D. Oncologia Toracica
Principal Investigator Name
Angelo Delmonte
Principal Investigator Email
angelo.delmonte@irst.emr.it
Contact Person Name
Angelo Delmonte
Contact Person Email
angelo.delmonte@irst.emr.it
Site Name
Fondazione Policlinico Universitario Agostino Gemelli IRCCS (additional listed site address)
Department Name
UOC Oncologia Medica
Principal Investigator Name
Emilio Bria
Principal Investigator Email
Emilio.bria@policlinicogemelli.it
Contact Person Name
Emilio Bria

Spain

Earliest CTIS Part Ii Submission Date
12-03-2026
Latest Decision Or Authorization Date
20-04-2026
Processing Time Days
39
Number Of Sites
16
Number Of Participants
30

Sites

Site Name
MD Anderson Cancer Center
Department Name
Oncology
Principal Investigator Name
Fernando Fábio Franco Pérez
Principal Investigator Email
ffranco@fundacionmdanderson.es
Contact Person Name
Fernando Fábio Franco Pérez
Contact Person Email
ffranco@fundacionmdanderson.es
Site Name
Hospital Universitario Fundacion Jimenez Diaz
Department Name
Oncology
Principal Investigator Name
Manuel Domine Gomez
Principal Investigator Email
mdomine@fjd.es
Contact Person Name
Manuel Domine Gomez
Contact Person Email
mdomine@fjd.es
Site Name
Instituto Oncologico Dr. Rosell S.L.
Department Name
Oncology
Principal Investigator Name
Roxana Reyes Cabanillas
Principal Investigator Email
rreyes@oncorosell.com
Contact Person Name
Roxana Reyes Cabanillas
Contact Person Email
rreyes@oncorosell.com
Site Name
Hospital Universitario Fundacion Jimenez Diaz (additional listed site)
Department Name
Oncology
Principal Investigator Name
Manuel Domine Gomez
Principal Investigator Email
mdomine@fjd.es
Contact Person Name
Manuel Domine Gomez
Contact Person Email
mdomine@fjd.es
Site Name
Institut Catala D'oncologia
Department Name
Oncology
Principal Investigator Name
Maria Saigi Morgui
Principal Investigator Email
uicico_badalona@iconcologia.net
Contact Person Name
Maria Saigi Morgui
Site Name
Hospital Universitario 12 De Octubre
Department Name
Oncology
Principal Investigator Name
Javier Torres Jimenez
Principal Investigator Email
javier.torres@salud.madrid.org
Contact Person Name
Javier Torres Jimenez
Contact Person Email
javier.torres@salud.madrid.org
Site Name
Hospital Quironsalud Malaga
Department Name
Oncology
Principal Investigator Name
Manuel Cobo Dols
Principal Investigator Email
manuelcobodols@yahoo.es
Contact Person Name
Manuel Cobo Dols
Contact Person Email
manuelcobodols@yahoo.es
Site Name
Complexo Hospitalario Universitario A Coruna
Department Name
Oncology
Principal Investigator Name
Maria del Rosario Garcia Campelo
Principal Investigator Email
ma.rosario.garcia.campelo@sergas.es
Contact Person Name
Maria del Rosario Garcia Campelo
Site Name
Clinica Universidad De Navarra (Madrid)
Department Name
Oncology
Principal Investigator Name
Miguel Fernandez de Sanmamed
Principal Investigator Email
msanmamed@unav.es
Contact Person Name
Miguel Fernandez de Sanmamed
Contact Person Email
msanmamed@unav.es
Site Name
Fundacion Instituto Valenciano De Oncologia
Department Name
Oncology
Principal Investigator Name
Sergio Sandiego Contreras
Principal Investigator Email
ssandiego@fivo.org
Contact Person Name
Sergio Sandiego Contreras
Contact Person Email
ssandiego@fivo.org
Site Name
Hospital Clinico Universitario De Valencia
Department Name
Oncology
Principal Investigator Name
Maria Insa Molla
Principal Investigator Email
ameliainsamolla@gmail.com
Contact Person Name
Maria Insa Molla
Contact Person Email
ameliainsamolla@gmail.com
Site Name
Hospital Del Mar
Department Name
Oncology
Principal Investigator Name
Edurne Arriola Aperribay
Principal Investigator Email
earriola@parcdesalutmar.cat
Contact Person Name
Edurne Arriola Aperribay
Contact Person Email
earriola@parcdesalutmar.cat
Site Name
Clinica Universidad De Navarra (Pamplona)
Department Name
Oncology
Principal Investigator Name
Miguel Fernandez de Sanmamed
Principal Investigator Email
msanmamed@unav.es
Contact Person Name
Miguel Fernandez de Sanmamed
Contact Person Email
msanmamed@unav.es
Site Name
Complejo Hospitalario Universitario Insular Materno Infantil
Department Name
Oncology
Principal Investigator Name
Delvys Rodriguez Abreu
Principal Investigator Email
drodabr@gobiernodecanarias.org
Contact Person Name
Delvys Rodriguez Abreu
Contact Person Email
drodabr@gobiernodecanarias.org
Site Name
Hospital General Universitario Gregorio Maranon
Department Name
Oncology
Principal Investigator Name
Rosa Maria Alvarez Alvarez
Principal Investigator Email
ralvareza@salud.madrid.org
Contact Person Name
Rosa Maria Alvarez Alvarez
Contact Person Email
ralvareza@salud.madrid.org
Site Name
Institut Catala D'oncologia (additional listed site)
Department Name
Oncology
Principal Investigator Name
Maria Saigi Morgui
Principal Investigator Email
uicico_badalona@iconcologia.net
Contact Person Name
Maria Saigi Morgui

Netherlands

Earliest CTIS Part Ii Submission Date
01-04-2026
Latest Decision Or Authorization Date
14-04-2026
Processing Time Days
13
Number Of Sites
2
Number Of Participants
10

Sites

Site Name
Leids Universitair Medisch Centrum (LUMC)
Department Name
Department of Pulmonary Diseases
Principal Investigator Name
Egbert Frederik Smit
Principal Investigator Email
e.f.smit@lumc.nl
Contact Person Name
Egbert Frederik Smit
Contact Person Email
e.f.smit@lumc.nl
Site Name
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
Department Name
Department of Pulmonary Diseases
Principal Investigator Name
Wilhelmina Sabina Marilyn Emilie Theelen
Principal Investigator Email
w.theelen@nki.nl
Contact Person Name
Wilhelmina Sabina Marilyn Emilie Theelen
Contact Person Email
w.theelen@nki.nl

Poland

Earliest CTIS Part Ii Submission Date
11-03-2026
Latest Decision Or Authorization Date
20-04-2026
Processing Time Days
40
Number Of Sites
5
Number Of Participants
10

Sites

Site Name
Med Polonia Sp. z o.o.
Department Name
Przychodnia MED-Polonia
Principal Investigator Name
Rodryg Ramlau
Principal Investigator Email
badania.kliniczne@medpolonia.com.pl
Contact Person Name
Rodryg Ramlau
Site Name
Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
Department Name
Klinika Nowotworów Płuca i Klatki Piersiowej
Principal Investigator Name
Dariusz Kowalski
Principal Investigator Email
Dariusz.kowalski@nio.gov.pl
Contact Person Name
Dariusz Kowalski
Contact Person Email
Dariusz.kowalski@nio.gov.pl
Site Name
Instytut Msf Sp. z o.o.
Department Name
Instytut MSF
Principal Investigator Name
Ewa Kalinka
Principal Investigator Email
Imsf.clinicaltrials@gmail.com
Contact Person Name
Ewa Kalinka
Contact Person Email
Imsf.clinicaltrials@gmail.com
Site Name
PRZYCHODNIA LEKARSKA ”KOMED” ROMAN KARASZEWSKI
Department Name
PRZYCHODNIA LEKARSKA ”KOMED”
Principal Investigator Name
Bogusława Karaszewska
Principal Investigator Email
komed.badania@gmail.com
Contact Person Name
Bogusława Karaszewska
Contact Person Email
komed.badania@gmail.com
Site Name
Uniwersyteckie Centrum Kliniczne
Department Name
Ośrodek Badań Klinicznych Wczesnych Faz
Principal Investigator Name
Dariusz Dziadziuszko
Principal Investigator Email
obkwf@uck.gda.pl
Contact Person Name
Dariusz Dziadziuszko
Contact Person Email
obkwf@uck.gda.pl

Sponsor

Primary sponsor

Full Name
Genmab A/S
Organisation Type
Pharmaceutical company
Country Of Registered Address
Denmark

Contract research organisations

Name
Icon Clinical Research Limited
Responsibilities
CRO

Third parties

  • {"country":"United Kingdom","full_name":"IQVIA Limited","duties_or_roles":"sponsorDuties codes: 4","organisation_type":"Pharmaceutical company"}
  • {"country":"United Kingdom","full_name":"Fortrea Development Limited","duties_or_roles":"sponsorDuties codes: 8","organisation_type":"Pharmaceutical company"}
  • {"country":"United States","full_name":"Mural Health Technologies Inc.","duties_or_roles":"Patient reimbursement support","organisation_type":"Laboratory/Research/Testing facility"}
  • {"country":"United States","full_name":"4g Clinical LLC","duties_or_roles":"sponsorDuties codes: 3","organisation_type":"Non-Pharmaceutical company"}
  • {"country":"Ireland","full_name":"Icon Clinical Research Limited","duties_or_roles":"CRO","organisation_type":"Pharmaceutical company"}

Investigational products

Investigational Product Name
Rinatabart Sesutecan
Active Substance
RINATABART SESUTECAN
Modality
ADC
Routes Of Administration
Intravenous infusion
Route
Intravenous infusion

Related trials

Other published trials that may interest you.